What is intralipid (intravenous lipid emulsion) and what are its indications, dosing regimens, and precautions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What are Intralipids?

Intralipid is a 20% intravenous lipid emulsion (fat emulsion) that serves two critical clinical roles: as a nutritional source of calories and essential fatty acids in parenteral nutrition, and as a life-saving antidote for local anesthetic systemic toxicity (LAST) and other lipophilic drug poisonings. 1, 2

Composition and Mechanism

Intralipid 20% is manufactured by Baxter Healthcare Corporation and consists of a fat emulsion that mimics natural chylomicrons in metabolism 3. The lipid particles are hydrolyzed by endothelial lipoprotein lipase, with the liver removing remnant particles 3.

For toxicity treatment, Intralipid works through two primary mechanisms:

  • "Lipid sink" phenomenon: Creates a lipid compartment in serum that extracts lipophilic drugs (particularly local anesthetics) from aqueous plasma and cardiac tissues 1, 4, 5
  • Cardiotonic effects: Counteracts local anesthetic inhibition of myocardial fatty acid oxidation, enabling energy production and reversing cardiac depression 1

Primary Indications

1. Parenteral Nutrition (FDA-Approved)

  • Source of calories and essential fatty acids for patients requiring parenteral nutrition >5 days 2
  • Prevention of essential fatty acid deficiency (EFAD) 2
  • Provides 2.0 kcal/mL with 20% concentration 3

2. Local Anesthetic Systemic Toxicity (LAST) - First-Line Treatment

Lipid rescue should be used in all cases of collapse secondary to local anesthetic toxicity 1. This is the strongest evidence-based indication, with Class 1, Level C-LD recommendation from the 2023 American Heart Association guidelines 6.

Intralipid 20% should be available in all hospitals offering maternity services 1.

3. Other Drug Toxicities - Second-Line/Rescue Therapy

Consider for severe cardiovascular instability from lipophilic drug poisonings including 3, 4, 6:

  • Beta-blockers
  • Calcium channel blockers
  • Tricyclic antidepressants
  • Tramadol, clozapine
  • Organophosphates

Dosing Regimens

For Local Anesthetic Toxicity (Cardiac Arrest/Severe Toxicity):

Initial bolus: 1.5 mL/kg of Intralipid 20% over 1 minute (100 mL for 70 kg patient) 1

Continuous infusion: 15 mL/kg/hour (1000 mL/hour for 70 kg patient) 1

Repeat boluses: Can repeat 1.5 mL/kg bolus twice at 5-minute intervals if circulation not restored 1

Escalation: After another 5 minutes, increase infusion to 30 mL/kg/hour if circulation not restored 1

Maximum cumulative dose: Do not exceed 12 mL/kg (840 mL for 70 kg patient) 1

Duration: Continue CPR throughout; resuscitation may take >1 hour 1

For Parenteral Nutrition:

Adults:

  • Initial rate: 0.5 mL/minute for first 15-30 minutes 2
  • If tolerated, increase to 1 mL/minute 2
  • Maximum: 2.5 g fat/kg/day (12.5 mL/kg of Intralipid 20%) 2
  • Should comprise ≤60% of total caloric input 2
  • Maximum infusion rate: 0.1 g/kg/hour 2

Pediatric patients:

  • Premature infants: Start 0.5 g fat/kg/24 hours (2.5 mL Intralipid 20%), maximum 3 g/kg/24 hours 2
  • Older children: Initial 0.05 mL/minute for 10-15 minutes, then 0.5 mL/kg/hour if tolerated 2
  • Maximum: 3 g fat/kg/day, ≤60% of total calories 2

For EFAD prevention: 8-10% of caloric input should be Intralipid 20% 2

Critical Precautions and Monitoring

Mandatory Monitoring:

  • Serum triglycerides: Monitor capacity to eliminate infused fat 2
    • Reduce dose if triglycerides exceed 3 mmol/L (265 mg/dL) in infants or 4.5 mmol/L (400 mg/dL) in older children 3
    • Keep below 12 mmol/L during treatment 7
  • Liver function tests: Monitor for parenteral nutrition-associated liver disease (PNALD), especially in pediatric patients receiving >2 weeks 2
  • Platelet counts: Frequent monitoring in neonates 2

Common Pitfalls to Avoid:

  1. Overdosage: Exceeding maximum cumulative dose can cause fat overload syndrome 3
  2. Infusion rate: Too rapid administration overwhelms lipoprotein lipase capacity 3
  3. Filter size: Use 1.2-micron filter; filters <1.2 microns will obstruct flow 2
  4. Hypertriglyceridemia: Temporarily discontinue if persistent (>72 hours) hypertriglyceridemia >12 mmol/L occurs 7

Adverse Effects (Rare but Serious):

  • Acute pancreatitis 3, 8
  • Fat overload syndrome (headaches, fever, hepatosplenomegaly, respiratory distress, coagulopathy) 3
  • Interference with laboratory testing 8, 9
  • Thrombocytopenia with prolonged use 3
  • Parenteral nutrition-associated liver disease (PNALD) in pediatric patients 2

Contraindications and Cautions:

  • Severe hyperlipidemia 2
  • Acute pancreatitis with hyperlipidemia 7
  • Pregnancy: Use only if clearly needed 2
  • Contains ≤25 mcg/L aluminum 2

Administration Guidelines

For toxicity treatment:

  • Stop injecting local anesthetic immediately if toxicity suspected 1
  • Can infuse via peripheral or central vein 2
  • May use Y-connector to mix with other solutions near infusion site 2
  • First-line treatment is lipid emulsion; consider cardiopulmonary bypass if available and refractory 1
  • All lipid rescue cases must be reported to NHS Improvement and the Lipid Rescue site (www.lipidrescue.org) 1

For parenteral nutrition:

  • Can be administered via peripheral or central vein 2
  • Central route preferred for prolonged therapy 7
  • Administer after adequate fluid resuscitation and hemodynamic stabilization (usually 24-48 hours from admission in critically ill) 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.